Unknown

Dataset Information

0

Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.


ABSTRACT: BACKGROUND AND PURPOSE:CD22 and CD79b are cell-surface receptors expressed on B-cell-derived malignancies such as non-Hodgkin's lymphoma (NHL). An anti-mitotic agent, monomethyl auristatin E, was conjugated to anti-CD22 and anti-CD79b antibodies to develop target-specific therapies for NHL. The mechanism of action (MOA) and pharmacological and pharmacokinetic (PK) profiles of these antibody-drug conjugates (ADCs) were investigated in cynomolgus monkeys. EXPERIMENTAL APPROACH:Animals were administered anti-CD22 or anti-CD79b ADCs, respective unconjugated antibodies or vehicle. Pharmacodynamic effects on total and proliferating B cells and serum PK were then assessed. Antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) of the ADCs were evaluated in vitro. KEY RESULTS:Depletion of B cells was observed after administration of either ADC or the respective unconjugated antibodies. An extended duration of depletion was observed in animals administered ADCs. Similarly, preferential depletion of proliferating B cells in blood and germinal centre B cells in spleen were only observed in animals administered ADCs. Serum PK profiles of ADCs and respective unconjugated antibodies were comparable. In vitro, anti-human CD22 and anti-human CD79b antibodies showed no or only moderate ADCC activity, respectively; neither antibody had CDC activity. CONCLUSIONS AND IMPLICATIONS:The findings support the proposed MOA: initial depletion of total B cells by antibody-mediated opsonization, followed by preferential, sustained depletion of proliferating B cells by the auristatin conjugate due to its anti-mitotic action. Delivering potent anti-mitotic agents to B cells via the specificity of monoclonal antibodies provides a means to eliminate pathogenic B cells in NHL with improved risk-benefit profiles over traditional chemotherapeutics.

SUBMITTER: Fuh FK 

PROVIDER: S-EPMC5368047 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background and purpose</h4>CD22 and CD79b are cell-surface receptors expressed on B-cell-derived malignancies such as non-Hodgkin's lymphoma (NHL). An anti-mitotic agent, monomethyl auristatin E, was conjugated to anti-CD22 and anti-CD79b antibodies to develop target-specific therapies for NHL. The mechanism of action (MOA) and pharmacological and pharmacokinetic (PK) profiles of these antibody-drug conjugates (ADCs) were investigated in cynomolgus monkeys.<h4>Experimental approach</h4>Anima  ...[more]

Similar Datasets

| S-EPMC5318162 | biostudies-literature
| S-EPMC6995165 | biostudies-literature
| S-EPMC6384886 | biostudies-literature
| S-EPMC6780994 | biostudies-literature
| S-EPMC4260046 | biostudies-literature
| S-EPMC6422391 | biostudies-literature
| S-EPMC8727762 | biostudies-literature
| S-EPMC6087439 | biostudies-literature
| S-EPMC4966491 | biostudies-literature
| S-EPMC7587605 | biostudies-literature